Rebamipide: evidence base for use in gastroenterology

Cover Page

Cite item

Full Text

Abstract

Rebamipide is a cytoprotective drug that has been used in practical gastroenterology for 30 years. This article summarizes the main results of the most relevant clinical studies of rebamipide in diseases of various parts of the gastrointestinal tract, including the esophagus, stomach, small and large intestine.

About the authors

D. N. Andreev

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112

к.м.н., доц. каф.

Russian Federation, Moscow

I. V. Maev

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X

акад. РАН, д.м.н, проф., зав. каф., засл. врач РФ, засл. деятель науки РФ

Russian Federation, Moscow

References

  1. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl. 1):S3-S11. doi: 10.1007/s10620-005-2800-9
  2. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70.
  3. Андреев Д.Н., Кулиева А.К. Механизмы действия ребамипида: систематизация литературных данных. Consilium Medicum. 2020;22(8):41-5 [Andreev DN, Kulieva AK. Mechanisms of action of rebamipide: systematic review. Consilium Medicum. 2020;22(8):41-5 (In Russ.)]. doi: 10.26442/20751753.2020.8.200373
  4. Звяглова М.Ю., Князев О.В., Парфенов А.И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020;92(2):104-11 [Zvyaglova MY, Knya- zev OV, Parfenov AI. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Therapeutic Archive. 2020;92(2):104-11 (In Russ.)]. doi: 10.26442/00403660.2020.02.000569
  5. Симаненков В.И., Тихонов С.В. Ребамипид – новые возможности гастроэнтеропротекции. Терапевтический архив. 2015;87(12):134-7 [Simanenkov VI, Tikhonov SV. Rebamipide: New opportunities of gastroenteroprotection. Therapeutic Archive. 2015;87(12):134-7 (In Russ.)]. doi: 10.17116/terarkh20158712134-137
  6. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003 Jul;18(Suppl. 1):8-13. doi: 10.1046/j.1365-2036.18.s1.5.x
  7. Murata H, Yabe Y, Tsuji S, et al. Gastro-protective agent rebamipide induces cyclooxygenease-2 (COX-2) in gastric epithelial cells. Dig Dis Sci. 2005 Oct;50(Suppl. 1):S70-5. doi: 10.1007/s10620-005-2809-0
  8. Tanigawa T, Watanabe T, Ohkawa F, et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr. 2011 Mar;48(2):149-53. doi: 10.3164/jcbn.10-75
  9. Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38(5):487-94. doi: 10.1080/1071576042000209808
  10. Kim CD, Kim YK, Lee SH, Hong KW. Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. J Pharmacol Exp Ther. 2000;294(3):864-9.
  11. Gweon TG, Park JH, Kim BW, et al.; Incheon and Western Kyonggi Gastrointestinal Study. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):46-50. doi: 10.5009/gnl17078
  12. Suzuki T, Yoshida N, Nakabe N, et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77. doi: 10.1254/jphs.fp0071422
  13. Lee KH, Kim JY, Kim WK, et al. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci. 2011;56(2):441-8. doi: 10.1007/s10620-010-1299-x
  14. Kang DW, Min G, Park DY, et al. Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells. Exp Mol Med. 2010 Aug 31;42(8):555-64. doi: 10.3858/emm.2010.42.8.056
  15. Min DS. A Potential Efficacy of Rebamipide as Anti-gastric Cancer Drug. J Life Sci. 2016;26(10):1214-7. doi: 10.5352/JLS.2016.26.10.1214
  16. Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-8. doi: 10.1159/000495288
  17. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа, 2019 [Maev IV, Busarova GA, Andreev DN. Diseases of the esophagus. Moscow: GEOTAR-Media, 2019 (In Russ.)].
  18. Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430-40. doi: 10.1136/gutjnl-2016-313589
  19. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Шабуров Р.И. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4-11 [Mayev IV, Andreev DN, Kucheryavy YuA, Shaburov RI. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophagoprotection. Therapeutic Archive. 2019;91(8):4-11 (In Russ.)]. doi: 10.26442/00403660.2019.08.000387
  20. Tobey NA, Hosseini SS, Argote CM, et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2004 Jan;99(1):13-22.
  21. Mönkemüller K, Wex T, Kuester D, et al. Role of tight junction proteins in gastroesophageal reflux disease. BMC Gastroenterol. 2012 Sep 20;12:128. doi: 10.1186/1471-230X-12-128
  22. Weijenborg PW, Smout AJ, Verseijden C, et al. Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis. Am J Physiol Gastrointest Liver Physiol. 2014 Aug 1;307(3):G323-9. doi: 10.1152/ajpgi.00345.2013
  23. Tan JC, Cui WX, Heng D, Lin L. ERK1/2 participates in regulating the expression and distribution of tight junction proteins in the process of reflux esophagitis. J Dig Dis. 2014 Aug;15(8):409-18. doi: 10.1111/1751-2980.12163
  24. Orlando LA, Orlando RC. Dilated intercellular spaces as a marker of GERD. Curr Gastroenterol Rep. 2009 Jun;11(3):190-4.
  25. Ивашкин В.Т., Трухманов А.С., Гоник М.И. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2020;92(4):98-104 [Ivashkin VT, Trukhmanov AS, Gonik MI. Rebamipide using in gastroesophageal reflux disease treatment. Therapeutic Archive. 2020;92(4):98-104 (In Russ.)]. doi: 10.26442/00403660.2020.04.000568
  26. Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55(12):3393-8. doi: 10.1007/s10620-010-1166-9
  27. Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016 Nov 15;10(6):910-6. doi: 10.5009/gnl15537
  28. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97 (In Russ.)]. doi: 10.22416/1382-4376-2020-30-4-70-97
  29. Contini S, Scarpignato C. Caustic injury of the upper gastrointestinal tract: a comprehensive review. World J Gastroenterol. 2013;19(25):3918-30. doi: 10.3748/wjg.v19.i25.3918
  30. Sy ML, Prieto RJ, Pang A, et al. Effectiveness of rebamipide in the prevention of esophageal stricture formation in advanced corrosive esophagitis: a prospective randomised control study. Gut 2018;67(Suppl. 2):A1-A118 A53. doi: 10.1136/gutjnl-2018-IDDFabstracts.118
  31. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Функциональная диспепсия. М.: Ремедиум, 2019 [Maev IV, Andreev DN, Kucheryavyy YuA. Functional dyspepsia. Moscow: Remedium, 2019 (In Russ.)].
  32. Mahadeva S, Ford AC. Clinical and epidemiological differences in functional dyspepsia between the East and the West. Neurogastroenterol Motil. 2016;28(2):167-74.
  33. Du L, Shen J, Kim JJ, et al. Impact of gluten consumption in patients with functional dyspepsia: A case-control study. J Gastroenterol Hepatol. 2018 Jan;33(1):128-33. doi: 10.1111/jgh.13813
  34. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014 Feb;63(2):262-71.
  35. Du L, Chen B, Kim JJ, et al. Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(4):e13304. doi: 10.1111/nmo.13304
  36. Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60.
  37. Miwa H, Osada T, Nagahara A, et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006;21(12):1826-31.
  38. Pittayanon R, Leelakusolvong S, Vilaichone RK, et al. Thailand Dyspepsia Guidelines: 2018. J Neurogastroenterol Motil. 2019;25(1):15-26.
  39. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015 [Maev IV, Samsonov AA, Andreev DN. Diseases of the stomach. Moscow: GEOTAR-Media, 2015 (In Russ.)].
  40. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
  41. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-9.
  42. Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-76.
  43. Li M, Yin T, Lin B. Rebamipide for chronic gastritis: a meta-analysis. Chinese J Gastroenterol Hepatol. 2015;24:667-73.
  44. Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862-7.
  45. Kamada T, Sato M, Tokutomi T, et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146.
  46. Han X, Jiang K, Wang B, et al. Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-73.
  47. Hou D, Yang M, Hu Z, Yang L. Effects of rebamipide for chronic atrophic gastritis: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(25):e20620.
  48. Маев И.В., Андреев Д.Н., Дичева Д.Т. Кислотозависимые заболевания. М.: Рекламное агентство «Ре Медиа», 2020 [Maev IV, Andreev DN, Dicheva DT. Acid-related diseases. Moscow: Advertising agency «Re Media», 2020 (In Russ.)].
  49. Lanas A, Chan FK. Peptic ulcer disease. Lancet. 2017;390(10094):613-24. doi: 10.1016/S0140-6736(16)32404-7
  50. Del Valle J. Peptic ulcer disease and related disorders. In: Kasper DL, Fauci AS, Hauser SL, et al., eds. Harrison’s Principles of Internal Medicine (19th edn). New York, NY: McGraw Hill Education, 2015; p. 1911-32.
  51. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006 Jul;19(3):449-90. doi: 10.1128/CMR.00054-05
  52. Terano A, Arakawa T, Sugiyama T, et al.; Rebamipide Clinical Study Group. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007 Aug;42(8):690-3.
  53. Song KH, Lee YC, Fan DM, et al. Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study. Digestion. 2011;84(3):221-9.
  54. Мартынов А.И., Шептулин А.А., Маев И.В. и др. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):7-14 [Martynov AI, Sheptulin AA, Mayev IV, et al. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7-14 (In Russ.)]. doi: 10.22416/1382-4376-2020-30-2-7-14
  55. Wang J, Guo X, Ye C, et al. Efficacy and safety of proton pump inhibitors (PPIs) plus rebamipide for endoscopic submucosal dissection-induced ulcers: a meta-analysis. Intern Med. 2014;53(12):1243-8.
  56. Nishizawa T, Suzuki H, Kanai T, Yahagi N. Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis. J Clin Biochem Nutr. 2015;56(2):85-90.
  57. Ивашкин В.Т., Маев И.В., Царьков П.В. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70 [Ivashkin VT, Maev IV, Tsar’kov PV, et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70 (In Russ.)]. doi: 10.22416/1382-4376-2020-30-1-49-70
  58. Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Клиническое значение инфекции Helicobacter pylori. Клин. мед. 2013;91(8):4-12 [Maev IV, Samsonov AA, Andreev DN, et al. Clinical significance of Helicobacter pylori infection. Klin Med (Mosk). 2013;91(8):4-12 (In Russ.)].
  59. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
  60. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro.2016.04.006
  61. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
  62. Zhou L, Sung JJY, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J. 2003;116:11-4.
  63. Okubo M, Tahara T, Shibata T, et al. Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. J Gastroenterol 2011;46:175-82.
  64. Lee YC, Chen THH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676-82.
  65. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
  66. Андреев Д.Н., Маев И.В., Дичева Д.Т. и др. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32 [Andreev DN, Maev IV, Dicheva DT, et al. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32
  67. Hayashi S, Sugiyama T, Amano K, et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998 Aug;42(8):1895-9.
  68. Nishizawa T, Nishizawa Y, Yahagi N, et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(Suppl. 4):20-4. doi: 10.1111/jgh.12769
  69. Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019 Sep 19;8(9):1498. doi: 10.3390/jcm8091498
  70. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. РЖГГК. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70 (In Russ.)]. doi: 10.22416/1382-4376-2018-28-1-55-70
  71. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2007;23(2):134-41. doi: 10.1097/MOG.0b013e328020045a
  72. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl. 3):S3.
  73. Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0
  74. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29 [Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29 (In Russ.)]. doi: 10.14412/1995-4484-2018-1-29
  75. Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94(7):1357-73. doi: 10.1016/j.mayocp.2019.01.018
  76. Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380-9. doi: 10.1111/jgh.14872
  77. Takagi T, Naito Y, Uchiyama K, et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011 Sep 7;17(33):3802-9. doi: 10.3748/wjg.v17.i33.3802
  78. Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci. 2005 Dec;50(12):2323-9. doi: 10.1007/s10620-005-3055-1
  79. Miyata M, Kasugai K, Ishikawa T, et al. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig Dis Sci. 2005 Oct;50(Suppl. 1):S119-23. doi: 10.1007/s10620-005-2816-1
  80. Furuta R, Ando T, Watanabe O, et al. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol. 2007;22(2):261-7. doi: 10.1111/j.1440-1746.2006.04399.x
  81. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492
  82. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38. doi: 10.5114/pg.2018.80001
  83. Bockerstett KA, DiPaolo RJ. Regulation of Gastric Carcinogenesis by Inflammatory Cytokines. Cell Mol Gastroenterol Hepatol. 2017 Mar 14;4(1):47-53.
  84. Zawada AE, Moszak M, Skrzypczak D, Grzymisławski M. Gastrointestinal complications in patients with diabetes mellitus. Adv Clin Exp Med. 2018 Apr;27(4):567-72. doi: 10.17219/acem/67961
  85. Kurniawan AH, Suwandi BH, Kholili U. Diabetic Gastroenteropathy: A Complication of Diabetes Mellitus. Acta Med Indones. 2019;51(3):263-71.
  86. Park S, Park SY, Kim YJ, et al. Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2016;40(3):240-7. doi: 10.4093/dmj.2016.40.3.240
  87. Парфенов А.И., Белостоцкий Н.И., Хомерики С.Г. и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование. Терапевтический архив. 2019;91(2):25-31 [Parfenov AI, Belostotsky NI, Khomeriki SG, et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Therapeutic Archive. 2019;91(2):25-31 (In Russ.)]. doi: 10.26442/00403660.2019.02.000123

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure: 1. Dynamics of the number of scientific papers on rebamipide in the text bibliographic databases PubMed / MEDLINE and RSCI.

Download (109KB)
Indexing metadata
3. Figure: 2. Diseases and pathological conditions of the gastrointestinal tract, in which the clinical efficacy of rebamipide was studied.

Download (136KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies